obesity leader faces supply hurdles as stock soars By Investing.com
Novo Nordisk (NYSE:) A/S, the Danish pharmaceutical giant with a market capitalization of $469.7 billion, has established itself as a leader in the rapidly growing market for diabetes and obesity treatments. With its blockbuster GLP-1 drugs like Ozempic and Wegovy driving impressive revenue growth of 26.15% over the last twelve months, the company faces both significant opportunities and challenges as it works to expand manufacturing capacity and fend off increasing competition. According to InvestingPro, the company maintains a “GREAT” financial health score of 3.25 out of 5, reflecting its strong market position. This comprehensive analysis examines Novo Nordisk’s current position, future prospects, and the factors that could impact…
